Evidence map›Paper›PMID 28827631›Full record

ArticleScientific reports2017

Improved efficacy and in vivo cellular properties of human embryonic stem cell derivative in a preclinical model of bladder pain syndrome.

Aram Kim, Hwan Yeul Yu, Jisun Lim, Chae-Min Ryu, Yong Hwan Kim, Jinbeom Heo, Ju-Young Han, Seungun Lee, Yoon Sung Bae, Jae Young Kim and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Micro-endoscopy for Live Small Animal Fluorescent Imaging.Advances in experimental medicine and biology · 2021
    Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 1 country.

Aram KimDepartment of Urology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, 05029, Korea.
Hwan Yeul YuDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea.
Jisun LimDepartment of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea.
Chae-Min RyuDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea.
Yong Hwan KimDepartment of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea.
Jinbeom HeoDepartment of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea.
Ju-Young HanDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea.
Seungun LeeDepartment of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea.
Yoon Sung BaeBiomedical Engineering Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea.
Jae Young KimBiomedical Engineering Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea.
Dong-Jun BaeASAN Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea.
Sang-Yeob KimASAN Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea.
Byeong-Joo NohDepartment of pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea.
Ki-Sung HongDepartment of Stem Cell Biology, School of Medicine, Konkuk University, Seoul, 05029, Korea.
Ji-Yeon HanPusan National University Yangsan Hospital, Pusan National University School of Medicine, Pusan, 50612, Korea.
Sang Wook LeeDepartment of Urology, Kangwon National University Hospital, Chunchon, Kangwon-do, 24289, Korea.ORCID 0000-0003-0497-5916
Miho SongDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea.
Hyung-Min ChungDepartment of Stem Cell Biology, School of Medicine, Konkuk University, Seoul, 05029, Korea.
Jun Ki KimBiomedical Engineering Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea.
Dong-Myung ShinDepartment of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea. d0shin03@amc.seoul.kr.ORCID 0000-0002-0511-5750
Myung-Soo ChooDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea. mschoo@amc.seoul.kr.
Ulsan College · KRKonkuk University · KRKonkuk University Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interstitial cystitis/bladder pain syndrome (IC/BPS) is an intractable disease characterized by severe pelvic pain and urinary frequency. Mesenchymal stem cell (MSC) therapy is a promising approach to treat incurable IC/BPS. Here, we show greater therapeutic efficacy of human embryonic stem cell (hESC)-derived multipotent stem cells (M-MSCs) than adult bone-marrow (BM)-derived counterparts for treating IC/BPS and also monitor long-term safety and in vivo properties of transplanted M-MSCs in living animals. Controlled hESC differentiation and isolation procedures resulted in pure M-MSCs displaying typical MSC behavior. In a hydrochloric-acid instillation-induced IC/BPS animal model, a single local injection of M-MSCs ameliorated bladder symptoms of IC/BPS with superior efficacy compared to BM-derived MSCs in ameliorating bladder voiding function and histological injuries including urothelium denudation, mast-cell infiltration, tissue fibrosis, apoptosis, and visceral hypersensitivity. Little adverse outcomes such as abnormal growth, tumorigenesis, or immune-mediated transplant rejection were observed over 12-months post-injection. Intravital confocal fluorescence imaging tracked the persistence of the transplanted cells over 6-months in living animals. The infused M-MSCs differentiated into multiple cell types and gradually integrated into vascular-like structures. The present study provides the first evidence for improved therapeutic efficacy, long-term safety, and in vivo distribution and cellular properties of hESC derivatives in preclinical models of IC/BPS.

Indexed as

Mesenchymal Stem Cell TransplantationPain ManagementAnimalsBiomarkersCystitis, InterstitialDisease Models, AnimalFluorescent Antibody TechniqueHuman Embryonic Stem CellsHumansImmunohistochemistryIntercellular Signaling Peptides and ProteinsKaryotypeMicroscopy, ConfocalMolecular ImagingPainSignal TransductionBiomarkersIntercellular Signaling Peptides and ProteinsWnt Proteins

Identifiers

PMID28827631
PMCPMC5567131
OpenAlexW2748124918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.